CAM
ASND icon

Cresset Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Cresset Asset Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,605
Closed -$244K – 1846
2023
Q3 		$244K Buy
+2,605
New +$244K ﹤0.01% 1537

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Cresset Asset Management's ASND Position: Q4 2023 in Review

Cresset Asset Management sold out of Ascendis Pharma A/S (ASND) in Q4 2023, closing a stake of 2,605 shares — an estimated $244K sold.

Cresset Asset Management first reported a position in ASND in Q3 2023 and held it in 1 quarter. The position peaked at $244K in Q3 2023. 185 funds tracked by Wall St. Rank hold ASND as of Q4 2023.

  • Cresset Asset Management reported no remaining Ascendis Pharma A/S position as of Q4 2023 after selling out during the quarter.
  • Cresset Asset Management sold 2,605 Ascendis Pharma A/S shares in Q4 2023, an estimated $244K.
  • Cresset Asset Management first reported a position in Ascendis Pharma A/S in Q3 2023 and held it in 1 quarter.
  • Cresset Asset Management's Ascendis Pharma A/S position peaked at $244K in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2023.

Based on Cresset Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.